[ad_1] MUNICH-Pfizer's Ibrance may have narrowly failed to show it could help relapsed breast cancer patients live longer. But execs contend its recent results still make a "compelling" case. In a phase …
Read More »ESMO: Pfizer's narrow survival Ibrance miss could still sway docs in its favor: exec
